netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Capecitabine found 16 matches

Formulary items 3 matches
   
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Capecitabine Malignant disease and immunosuppression - Antimetabolites - 08.01.03
  Cytotoxic Drug Gemcitabine Malignant disease and immunosuppression - Antimetabolites - 08.01.03
  Cytotoxic Drug Tucatinib  (Tukysa®) Malignant disease and immunosuppression - Protein kinase inhibitors - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (Jan 2014): Capecitabine: risk of severe skin reactions - discontinue treatment (08.01.03)
link in drug section MHRA Drug Safety Update (Oct 2020): 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity (08.01.03)
link in drug section MHRA Drug Safety Update (Oct 2020): 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity (08.01.03)
link in drug section MHRA Drug Safety Update (Oct 2020): 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity (08.01.03)
link in drug section MHRA Drug Safety Update (Oct 2020): 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity (08.01.03)
link in drug section NHS England SSC1959 - Clinical Commissioning Policy: Gemcitabine and capecitabine following surgery for pancreatic cancer (all ages) (08.01.03)
link in drug section NHS England SSC1959 - Clinical Commissioning Policy: Gemcitabine and capecitabine following surgery for pancreatic cancer (all ages) (08.01.03)
link in drug section NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (08.01.05)
link in drug section NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin (08.01.03)
link in drug section NICE TA191: Gastric cancer (advanced) - capecitabine (08.01.03)
link in drug section NICE TA61: Colorectal cancer - capecitabine and tegafur uracil (08.01.03)
link in drug section NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (08.01.03)
link in drug section NICE TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (08.01.05)


 
netFormulary